10x Genomics Reports Q4 & FY25 Results, Projects Flat to Low Growth for 2026

summarizeSummary

10x Genomics reported a significant reduction in net loss for Q4 and full-year 2025, but core revenue declined in 2025 and 2026 guidance indicates flat to low single-digit growth.

check_boxKey Events

• Q4 & FY2025 Financials Reported

  The company reported Q4 2025 revenue of $166.0 million (1% YoY increase) and full-year 2025 revenue of $642.8 million (5% YoY increase).

• Core Revenue Declined in 2025

  Full-year 2025 revenue, excluding $44.1 million from patent litigation settlements, was $598.7 million, representing a 2% decrease from 2024.

• Significant Reduction in Losses

  Operating loss significantly decreased to $61.0 million for full-year 2025 from $194.6 million in 2024, and net loss improved to $43.5 million from $182.6 million.

• 2026 Revenue Guidance Provided

  The company projected full-year 2026 revenue between $600 million and $625 million, indicating 0% to 4% growth over adjusted 2025 revenue.

auto_awesomeAnalysis

10x Genomics' latest financial report presents a mixed picture for investors. While the company achieved a substantial reduction in its operating and net losses for both the fourth quarter and full year 2025, demonstrating improved cost control and efficiency, its core revenue growth remains challenged. Excluding non-recurring patent litigation settlements, full-year 2025 revenue decreased by 2% year-over-year. The provided 2026 revenue guidance of $600 million to $625 million, which represents 0% to 4% growth over adjusted 2025 revenue, suggests continued headwinds for top-line expansion. Investors will likely focus on the weak revenue trajectory despite the positive developments in profitability and strategic partnerships. The strong cash position provides financial flexibility.